z-logo
Premium
Fibroblast growth factor receptor‐1 as a potential therapeutic target in sinonasal cancer
Author(s) -
Schröck Andreas,
Göke Friederike,
Wagner Patrick,
Bode Maike,
Franzen Alina,
Huss Sebastian,
Agaimy Abbas,
Ihrler Stephan,
Kirsten Robert,
Kristiansen Glen,
Bootz Friedrich,
Lengerke Claudia,
Perner Sven
Publication year - 2014
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23443
Subject(s) - fibroblast growth factor receptor 1 , fluorescence in situ hybridization , adenoid cystic carcinoma , medicine , pathology , cancer , cancer research , lymph node , adenocarcinoma , esthesioneuroblastoma , carcinoma , oncology , biology , fibroblast growth factor , receptor , radiation therapy , gene , biochemistry , chromosome
Background Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 ( FGFR1 ) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer. Methods One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker. Results FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1 ‐amplified tumors expressed p16. Conclusion FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer. © 2014 Wiley Periodicals, Inc. Head Neck 36: 1253–1257, 2014

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom